Valneva (VALN)
NASDAQ:VALN
Earnings Data
Report Date
May 07, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.16Last Year’s EPS
-0.14Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a balanced mix of strategic and operational positives — stable revenues, proprietary product growth (notably IXIARO), strengthened liquidity and important near‑term clinical milestones (Lyme Phase III readout, Shigella Phase II data). Offsetting these positives were significant near‑term financial pressures: an operating loss and net loss in 2025, inventory write‑downs and persistent idle manufacturing costs, higher R&D spend, and uncertainty over timing of pivotal readouts and commercial milestone realization. The company is focused on cost discipline and pipeline advancement, but material upside from Lyme remains contingent on an external partner‑run readout and subsequent commercialization timing.Company Guidance
Stable Total Revenues and Product Sales
Total revenues exceeded EUR 170 million in FY2025 with product sales of EUR 157.9 million (down -3.3% YoY; -1.3% at constant currency), reflecting overall stability vs. 2024 despite FX headwinds and strategic reduction of third‑party sales.
Proprietary Product Growth
Proprietary product sales grew ~+9% year‑over‑year excluding currency effects. IXIARO sales rose to EUR 98.4 million (+4.6% YoY; +7.2% at constant currency). IXCHIQ sales increased to EUR 8.4 million from EUR 3.7 million (approx. +127%), including supply of 40,000 doses to La Réunion.
Improved Cash Position and Liquidity Actions
Year‑end cash position nearly EUR 110 million and the company completed a successful debt refinancing (new 5‑year product loan with Pharmakon), enhancing financial flexibility.
Reduced Operating Cash Burn and Cost Discipline
Management reported more than a 20% reduction in operating cash burn driven by disciplined cash management; marketing & distribution and G&A expenses were reduced (M&D down ~-28.6% to EUR 37.4 million; G&A down ~-12.9% to EUR 37.3 million).
One‑time Revenue Recognition Strengthens Other Income
Other revenues rose from EUR 6.3 million to EUR 16.8 million, driven largely by a EUR 10 million revenue recognition related to the Lyme agreement with Pfizer (previously recorded as a refund liability).
Advancing Key Pipeline Programs — Lyme (VLA15) Nearing Readout
Phase III VALOR study (approx. 10,000 participants) for VLA15 (Lyme vaccine, partnered with Pfizer) completed vaccinations and is anticipated to report pivotal data in H1 2026; management described this program as potentially transformational if positive.
Additional R&D Milestones Expected in 2026
Two Phase II programs for the tetravalent Shigella candidate (S4V2) — an infant study and a controlled human infection model — are ongoing with data expected mid‑2026; continued post‑marketing activities and a pilot vaccination campaign for IXCHIQ in Brazil are also underway.
Strategic Refocus on Proprietary Portfolio
Planned termination and reduction of third‑party distribution (third‑party sales reduced from EUR 33.2 million to EUR 19.2 million, ~-42%) reflects a deliberate shift to concentrate on company‑owned vaccines and higher margin opportunities.
VALN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VALN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 18, 2026 | $11.01 | $11.19 | +1.63% |
Nov 20, 2025 | $8.70 | $8.53 | -1.95% |
Aug 12, 2025 | $8.50 | $9.40 | +10.59% |
May 07, 2025 | $6.48 | $6.59 | +1.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Valneva (VALN) report earnings?
Valneva (VALN) is schdueled to report earning on May 07, 2026, TBA (Confirmed).
What is Valneva (VALN) earnings time?
Valneva (VALN) earnings time is at May 07, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VALN EPS forecast?
VALN EPS forecast for the fiscal quarter 2026 (Q1) is -0.16.